PapersPMID:30670010
A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia.
What moved
1 findingHow to read these marks →- Decreases total cholesterol (TC)
moderate
“The reduction in TC was highly significant (p = 0.0003) between amla extract and placebo group.”
- Study
- RCT
- Duration
- 3 months
- Interests
- Industry funded
- Dose studied
- 500 mg capsule twice daily, after breakfast and after dinner, for 12 weeks
- Population
- Adults aged 30 to 65 with dyslipidemia (TG > 200, LDL-C > 130, TC > 200 mg/dL, low HDL-C), 49 per arm, off lipid-lowering medication for 4 weeks; all patients also asked to start a healthy diet and exercise in both arms; fasting samples at 12 weeks
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Male and female dyslipidemic patients (TG > 200 mg/dL, LDL-C > 130 mg/dL, TC > 200 mg/dL, low HDL-C) at four centres in South India, not on dyslipidemia medication for 4 weeks
- Participants
- 98
- Comparator
- placebo
- Duration
- 84 days
- Endpoints measured
- 31